AUTHOR INDEX
Volume 34
July-December, 1986

Aedo, A.R., 469
Ahmad, M.M., 413
Albertson, B., 199
Alvarez, F., 261
Anderson, A.E., III, 435
Arce, B.B., 513
Ayerst, R.I., 435
Baird, D.T., 513, 459
Belhadj, H., 261
Belsey, E.M., 253
Betrabet, S.S., 169, 403
Bhatia, S., 177
Bhattacharya, K., 523
Bonnar, J., 603
Brache, V., 261
Breaux, H., 261
Bygdeman, M., 469
Cameron, I.T., 459
Castro, A., 353
Cekan, S.Z., 469
Champion, C.B., 505
Chan, W.Y., 537
Chen, J.K., 269
Cheng, D.H., 269
Chi, I.-C., 483, 497, 505
Chiang, S., 341
Chijioke, P.C., 207
Choi, H.L., 537
Chongthammakun, S., 323
Cleary, P.A., 121
Cong, J., 559
Croxatto, H., 613
Curtis, M.K., 435
d'Arcangues, C., 253
Datey, S., 403
Decarli, A., 145
de Leede, L.G.J., 589
de Nijs, H., 589
de Orchi, L., 549
Diaz, S., 261
Diczfalusy, E., 1
DiMattina, M., 199
Donaldson, A., 639
Dong, J., 559
Dostal, D.E., 303
Edelstein, J.A., 413
Ekavipat, C., 323
Ellsworth, H.S., 435
El-Tabbakh, G., 395
Falk, R.J., 199
Fan, H., 559
Feldblum, P.J., 505
Fotherby, K., 269
Franceschi, S., 145
Frick, J., 177
Galich, L.F., 483
Ganguly, T., 625
Gao, J., 559
Gawad, A.A., 395
Gawish, S., 395
Gentile, A., 145
Gler, S., 283
Goebelsmann, U., 341
Gottardi, G., 549
Govers, C.P.M., 589
Han, L., 559
Harris, J.W., 435
Hays, D., 413
Heikinheimo, O., 613
Hoffman, D., 341
Hofvander, Y., 443
Honoré, L.H., 213
Hourihan, H.M., 603
Indian Council of Medical Research Task Force on Hormonal Contraception, 573
Jeffcoate, S.L., 639
Johansson, E., 157
Johnson, J.A., 303
Jones, A.R., 311
Jones, T.L., 435
Kabir, S.N., 523
Kalla, N.R., 177
Kanders, B., 333
Kirkman, R.J.E., 513
Kloosterberg, H.J., 135
Lähteenmäki, P., 613
Lamptey, P., 505
LaRosa, J.C., 121
La Vecchia, C., 145
Leitch, W.S., 363, 381
Lindsay, R., 333
Lippes, J., 483
Lipson, A., 121
Liu, G.M., 295
Liu, W.Y., 269
Lohiya, N.K., 417
Loriaux, D.L., 199
Loudon, N.B., 513
Lu, Q.H., 295

Lu, Y.S., 295
Machin, D., 253
Matangkasombut, O.P., 191
McCarthy, T., 261
McNeilly, A.S., 513
Mellbin, T., 443
Méndez, F., 353
Michie, A.F., 459
Miller, V.T., 121
Mishell, D.R., Jr., 261
Mokhtar, A., 395
Muesing, R.A., 121
Nayel, S., 395
Negri, E., 145
Ng, T.B., 537
Nilsson, S., 443
Nygren, K.G., 443
Odlind, V., 157, 583
Olsson, S.-E., 157, 583
Opiniano, V., 283
Ortega, A., 353
O'Shaughnessy, P.J., 639
Osteria, T.S., 283
Pakrashi, A., 523, 625
Pal, A.K., 523, 625
Parazzini, F., 145
Patel, D.M., 169, 403
Pavasuthipaisit, K., 323
Pavez, M., 261
Pearce, S., 639
Pearson, R.M., 207
Qi, L.M., 295
Qian, Y.X., 295
Reid, T.-A., 311
Sanitwongs, B., 323
Saxena, B.N., 403
Sharma, O.P., 417
Sharma, R.C., 417
Shen, P.J., 295
Sheppard, B.L., 603
Shikary, Z.K., 403
Shoupe, D., 261, 613
Siemens, A.J., 483
Sivin, I., 261
Smith, S.K., 513
Somell, C., 189
Song, S., 269
Spreafico, A., 549
Stone, R.A., 435
Stumpf, P.G., 395
Sufi, S.B., 639
Sun, B., 559
Sun, P., 295
Sundelin, C., 443
Swahn, M.L., 469
Sy, F.S., 283
Tam, P.P.L., 537
Tauber, P.F., 483
Tejada, A.S., 111, 261
Temmerman, M., 529
Tevilin, M., 613
Tjia, J., 23, 51
Toddywala, V.S., 403
Tohme, J., 333
Trienekens, P.H., 503
Tunkeyoon, M., 159
Vaidya, P., 169
Valentin, J., 443
van den Ende, A., 135
van Wayjen, R.G.A., 135
Wang, G., 469
Waszak, C.S., 483, 497
White, I.G., 311
WHO Task Force on Long-Acting Systemic Agents for Fertility Regulation, 223
WHO Task Force on Prostaglandins for Fertility Regulation, 237
Wide, L., 583
Wilkens, L.R., 483, 497
Woutersz, T., 341
Wu, S., 559
Xie, Z., 559
Xu, R.Y., 295
Yang, H.Q., 295
Yang, P.J., 269
Yao, G.-Z., 443
Yarkoni, S., 533
Yeung, H.W., 537
Yo, V., 261
Zahran, M., 395
Zaman, S., 207
Zbella, E.A., 423
Zeng, S., 559
Zhang, R.W., 295
Zhu, X., 559

SUBJECT INDEX

Volume 34

July to December 1986

Abortion in early pregnancy,
use of RU486, 459
use of RU486 + 16,16-dimethyl-trans-Δ_2-PGE_1, 459
Acceptability, benzalkonium chloride spermicidal suppository, 353
Acid phosphatase level, effect of aristolic acid (mouse), 625
Adenylate cyclase activity in leydig cells, effect of gossypol (mouse), 639
Adjustable release of contraceptive steroids, multi-compartment vaginal ring system, 589
Alanine aminotransferase level, effect of mestranol + norethisterone, 283
Albumin level, effect of mestranol + norethisterone, 283
Alkaline phosphatase level,
effect of aristolic acid (mouse), 625
effect of mestranol + norethisterone, 283
Allitridum,
bacteriostatic test, 295
spermicidal effect, 295
vaginal irritation test (rabbit), 295
Analysis of vaginal bleeding patterns induced by fertility regulating methods, 253
Androstenedione level, effect of levonorgestrel, 157
Antifertility vaccines as fertility regulating method, 14
Antiprogestins, use as post-ovulatory methods of fertility regulation, 8
Apolipoproteins level,
effect of ethinyloestradiol + desogestrel, 135
effect of triphasic ethinyloestradiol + levonorgestrel, 135
Apoproteins level, effects of oral contraceptives containing progestins with varying androgenic potency, 121
Aristolic acid,
effect on pregnancy (mouse), 625
effect on uterus (mouse), 625
Arterial pressure during mestranol-induced hypertension, effects of captopril or bradykinin (rat), 303
Aspartate aminotransferase level, effect of mestranol + norethisterone, 283
Aspirin + gossypol, effect on testis function and histology (rat), 177
Bacteriostatic test, use of Allitridum, 295
Bank of reagents for immunoassay of hormones, WHO Programme in Human Reproduction, 76
Basic research, impact of WHO Special Programme in Human Reproduction, 86

Benzalkonium chloride suppository, effectiveness as vaginal contraceptive, 353
Bilirubin level, effect of mestranol + norethisterone, 283
Bioavailability study, ethinyl estradiol + levonorgestrel administered as tablet and as solution, 341
Biological activity,
  estrogenic component of endogenous steroids in breast milk, 169
  ethinyl estradiol present in breast milk, 169
Bleeding pattern, use of prostaglandin analogues or laminaria tent for preoperative cervical dilatation, 237
Blood pressure,
  effect of depot-medroxyprogesterone acetate, 223
  effects of oral contaceptives containing progestins with varying androgenic potency, 121
Body and organ weights,
  effect of gossypol (rat), 177
  effect of gossypol + aspirin (rat), 177
  effect of gossypol + $PGF_{2\alpha}$ (rat), 177
Bone mineral density in pre- and post-menopausal women, effects of oral contaceptive use, 333
Bradykinin, effect on arterial pressure during mestranol-induced hypertension (rat), 303
Breast milk, biological activity of estrogenic component, 169
Breast-fed children, long-term follow-up when mothers used oral contraceptives, 443
Breast-fed male infants, pharmacodynamic effects of levonorgestrel when administered to lactating mothers, 403
Breast-feeding period, use of oral contraceptives, 443
Captopril, effect on arterial pressure during mestranol-induced hypertension (rat), 303
Cardiovascular disease and oral contraceptives, 28
Ceruloplasmin level, effect of norethisterone, 269
Cervical cap, longevity of potency of spermicides used, 363
Cervical dilatation, use of prostaglandin analogues or laminaria tent, 237
Chlorhexidine, concentration abolishing sperm motility, 207
Chlorinated antifertility agents, mechanism of inhibition of fructolysis in spermatozoa (ram), 311
1-Chloro-3-hydroxyacetone, effect on metabolic activity of ejaculated spermatozoa (ram), 311
6-Chloro-6-deoxyglucose, effect on metabolic activity of ejaculated spermatozoa (ram), 311
Cholesterol levels,
  effect of ethinyloestradiol + desogestrel, 135
  effect of norethisterone, 269
  effect of triphasic ethinyl estradiol + levonorgestrel, 135, 435
  effects of oral contraceptives containing progestins with varying androgenic potency, 121
Chromosorb® column chromatography, use in quantitation of RU 486, 613

Clinical symptoms, use of triphasic ethinyl estradiol + levonorgestrel, 435
Collaborating Centres for Research, WHO network of clinical research centres in human reproduction, 50
Contraceptive diaphragm, longeviConception rate,
following discontinuation of CuT 200, 573
following discontinuation of norethisterone oenanthate, 573
Continuation,
IUD users, 549
postcoital IUD insertion, 549
Contraceptive diaphragm, longevity of Ortho Creme® and Gynol II®, 381
Contraceptive efficacy, depot-medroxyprogesterone acetate, 223
Coordination and collaboration with other agencies, WHO Programme in Human Reproduction, 82
Cu-7, case report of perforation of sigmoid colon, 413
Current methods of fertility regulation, safety and efficacy, 24
CuT 200, return of fertility following discontinuation, 573
Cyclic AMP production in leydig cells, effect of gossypol (mouse), 639
Danazol (17α-pregn-4-en-20-yno-(2,3-d)isoxazol-17-01)
Danazol + testosterone enanthate, effect on testis functions and sexual potentia (monkey), 417
Dehydroepiandrosterone, effect on progesterone production by granulosa cells, 199
9-Deoxo-16,16-dimethyl-9-methylene PGE_2, use for preoperative cervical dilatation, 237
Depot-medroxyprogesterone acetate,
clinical trial, 223
pharmacokinetic and pharmacodynamic studies, 26
safety and efficacy studies, 26
Determinants of oral contraceptive use, 145
Developing countries, impact of WHO Programme in Human Reproduction, 84
Diaphragm, longevity of potency of spermicides used, 381
Diazepam, effect on postcoital contraceptive efficacy of ethinyl estradiol (rat), 191
16,16-Dimethyl-trans-Δ_2-PGE_1 + RU486, use in early pregnancy termination, 459
16,16-Dimethyl-trans-Δ_2-PGE_1 methyl ester, use for preoperative cervical dilatation, 237
Discontinuation,
use of CuT 200, 573
use of mestranol + norethisterone, 283
use of northisterone oenanthate, 573
use of triphasic ethinyl estradiol + levonorgestrel, 435
Discontinuation rate, depot-medroxyprogesterone acetate, 223
Dissemination of information, WHO Programme in Human Reproduction, 84
Drug regulatory process, WHO Programme in Human Reproduction, 80

Dysfunctional uterine bleeding, morphometric study on endometrial blood vessels, 603
Ectopic pregnancy, relation to IUD use, 31
Efficacy, triphasic ethinyl estradiol + levonorgestrel, 435
Embryo, effects of momorcharins (mouse), 537
Endometrial bleeding, multicentre studies, 50
Endometrial blood vessels,
  effect of norethisterone or levonorgestrel on morphometric study, 603
  morphometric study during menstrual cycle, 603
  morphometric study on women with dysfunctional uterine bleeding, 603
Estradiol level,
  effect of ethinyl estradiol + levonorgestrel, 513
  effect of norethisterone, 269
  effect of triphasic ethinyl estradiol + levonorgestrel, 513
Estrogen bioassay (mouse), 169
Ethical issues, WHO Programme in Human Reproduction, 77
Ethinyl estradiol,
  biological activity when present in breast milk, 169
  effect on postcoital contraceptive efficacy when given together with diazepam or phenobarbital sodium (rat), 191
  release rate from one-, two-, or three-compartment vaginal ring system, 589
Ethinyl estradiol + ethynodiol diacetate, effect on lipoproteins, 121
Ethinylestradiol + 3-keto-desogestrel, multi-compartment vaginal ring system, 589
Ethinyl estradiol + levonorgestrel,
  bioavailability study when administered as tablet and as solution, 341
  clinical and metabolic effects, 435
  effect of deliberate pill omission on hypothalamo-pituitary-ovarian axis, 513
  effect on lipid metabolism, 135
Ethinyl estradiol + norethindrone acetate, effect on lipoproteins, 121
Ethinylestradiol + norethisterone acetate, effect on nickel concentration, 395
Ethinyl estradiol + dl-norgestrel, effect on lipoproteins, 121
Ethinyl estradiol level, administered in combination with levonorgestrel as tablet and as solution, 341
Ethinyloestradiol + desogestrel, effect on lipid metabolism, 135
Expulsion,
  effect of IUD insertion-related problems, 497
  use of IUDs, 559
External Quality Assessment Programme, 72
Failures in female sterilization using tubal ring, associated risk factors, 505
Family formation patterns and health, 44
Female sterilization, 22

Female sterilization, characteristics predisposing to failure using tubal ring procedure, 505
Ferritin concentration, use of IUDs, 559
Fertility recovery,
after use of CuT 200, 573
after use of levonorgestrel-releasing or TCu 380 Ag IUD, 261
following discontinuation of norethisterone oenanthate, 573
Fertility regulating methods, analysis of vaginal bleeding patterns, 253
Fructolysis in spermatozoa, mechanism of inhibition by chlorinated antifertility agents (ram), 311
FSH (follicle stimulating hormone)
FSH level,
effect of ethinyl estradiol + levonorgestrel, 513
effect of triphasic ethinyl estradiol + levonorgestrel, 513
in breast-fed male infants when levonorgestrel administered to lactating mothers, 403
Future prospects, WHO Special Programme of Research, Development and Research Training in Human Reproduction, 90
Glucose level,
effect of norethisterone, 269
effect of triphasic ethinyl estradiol + levonorgestrel, 435
Glycosylated haemoglobin level, effect of norethisterone, 269
Gossypol (1,1,6,6,7,7-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl[2,2'-binaphthalene]-8,8'-dicarboxaldehyde),
effect on leydig cells (mouse), 639
effect on testicular and liver cell membranes (mouse), 639
effect on testis function and histology (rat), 177
Gossypol + aspirin, effect on testis function and histology (rat), 177
Gossypol + $PGF_{2\alpha}$, effect on testis function and histology (rat), 177
Gossypol acetic acid,
effect on sperm motility, 323
effect on sperm motility (monkey), 323
Group statistics, used in describing vaginal bleeding patterns, 253
Gynol II®,
longevity of spermicidal potency in cervical cap, 363
longevity of spermicidal potency in contraceptive diaphragm, 381
Haemoglobin concentration, use of IUDs, 559
hCG (human chorionic gonadotropin)
β-hCG vaccine, immunological approach to fertility regulation, 14
Hibiscus rosa-sinensis flower, interceptive effect of benzene extract (mouse), 523
Hibiscus rosa-sinensis flower benzene extract, effect of progesterone, prolactin or human chorionic gonadotropin on interceptive effect (mouse), 523

High-performance-liquid chromatography, RU 486, 613
Hormone levels,
effect of gossypol (rat), 177
effect of gossypol + aspirin (rat), 177
effect of gossypol + $PGF_{2\alpha}$ (rat), 177
Hydatidiform mole, negative association with IUCD *in situ*, 213
3β-Hydroxysteroid dehydrogenase activity, effect of RU486, 199
Δ^5-3β-Hydroxysteroid dehydrogenase activity, effect of benzene extract of *Hibiscus rosa-sinensis* flower (mouse), 523
Hypertension produced by mestranol, effects of captopril or bradykinin on arterial pressure (rat), 303
Identification of sub-groups, used in describing vaginal bleeding patterns, 253
Impact of the programme, WHO Special Programme of Research, Development and Research Training in Human Reproduction, 84
Implantable steroidal contraceptives, 5
Induced abortions, assessment of sequelae, 30
Infertility,
evaluation of diagnostic procedures, 38
influence of varicocele, 38
prevalence, 34
primary health care, 38
standardized investigation of the infertile couple, 36
treatment, 40
Injectable contraceptive,
depot-medroxyprogesterone acetate, 223
field trials, 47
multicentre studies, 50
norethisterone oenanthate, 573
Injectable steroidal contraceptives, 5
Insertion of IUD, risk factors associated with severe pain, 483
Insertion-related problems with IUD, effect on subsequent performance, 497
Institution strengthening in developing countries,
African region, 64
American region, 64
South-East Asia region, 64
Western Pacific region, 64
Insulin level,
effect of norethisterone, 269
effect of triphasic ethinyl estradiol + levonorgestrel, 435
Intellectual capacity, children breast-fed by mothers using oral contraceptives, 443
Interceptive effect, benzene extract of *Hibiscus rosa-sinensis* flower (mouse), 523
Interceptive postcoital method, IUD insertion, 549

Intrauterine device (IUCD or IUD),
Cu-7, 413
CuT 200, 573
effect of insertion-related problems on subsequent performance, 497
effect on development of molar pregnancies, 213
effectiveness as postcoital contraception, 549
menstrual blood loss studies, 11
miniCu 7, 549
ML250, 549
multicentre studies, 50
performance in international multicentre studies, 11
releasing levonorgestrel, 261
risk factors associated with severe pain at insertion, 483
safety and efficacy studies, 11
Steel Ring, 559
TCu 200, 549
TCu 220c, 559
TCu 380 Ag, 261
VCu 200, 559
IUCD or IUD (intrauterine device)
3-Keto-desogestrel, release rate from one-, two- or three-compartment vaginal ring system, 589
Laminaria tent, use for preoperative cervical dilatation, 237
Levonorgestrel,
effect on androgen levels, 157
effect on thyroid function, 583
effects in breast-fed male infants, 403
pharmacodynamic effects, 403
L morphometric study on endometrial blood vessels, 603
pharmacodynamic effects, 403
Levonorgestrel level,
administered in combination with ethinyl estradiol as tablet and as solution, 341
use of subdermal implants releasing levonorgestrel, 157
Levonorgestrel-releasing IUD, recovery of fertility after use, 261
Leydig cells, effect of gossypol (mouse), 639
LH (luteinizing hormone)
LH level,
effect of ethinyl estradiol + levonorgestrel, 513
effect of triphasic ethinyl estradiol + levonorgestrel, 513
in breast-fed male infants when levonorgestrel administered to lactating mothers, 403
Lifestyle habits, effect on oral contraceptive use, 145
Lipid and lipoprotein changes, effects of oral contraceptives containing progestins with varying androgenic potency, 121
Lipid metabolism,
effect of ethinyloestradiol + desogestrel, 135
effect of triphasic ethinyl estradiol + levonorgestrel, 135, 435

Lipoprotein fractions,
effect of ethinyloestradiol + desogestrel on lipid content, 135
effect of triphasic ethinyloestradiol + levonorgestrel on lipid content, 135
Lipoproteins level, effect of triphasic ethinyl estradiol + levonorgestrel, 435
Liver cell membranes, effect of gossypol (mouse), 639
Liver function tests of women with schistosomiasis, effect of mestranol + norethisterone, 283
Long-acting systemic contraceptive methods,
development of new and improved formulations, 5
multicentre studies, 50
research on safety and efficacy, 5
safety and efficacy, 26
Male contraceptive, danazol + testosterone enanthate (monkey), 417
Male fertility regulation methods, 18
Mandate, WHO Special Programme of Research, Development and Research Training in Human Reproduction, 3
Medical conditions, effect on oral contraceptive use, 145
Menstrual blood loss, use of IUDs, 559
Menstrual blood loss and sterilization, 33
Menstrual cycle,
effect of triphasic ethinyl estradiol + levonorgestrel, 435
vessel density of endometrium during different phases, 603
Menstrual diaries, use in analysis of vaginal bleeding patterns, 253
Menstruation, patterns and perceptions, 44
Mental health and female sterilization, 33
Mestranol + norethisterone, effect on liver function tests of women with schistosomiasis, 283
Mestranol-induced hypertension, effects of captopril and bradykinin on arterial pressure (rat), 303
Metabolic activity of ejaculated spermatozoa, effect of chlorinated antifertility agents (ram), 311
Method development, diagnostic techniques for use in WHO studies, 75
15-Methyl-$PGF_{2\alpha}$ methyl ester, use for preoperative cervical dilatation, 237
Molar pregnancy development, effect of IUCD *in situ*, 213
Momorcharins,
effects on embryo (mouse), 537
effects on visceral yolk sac (mouse), 537
Momordica charantia L. seeds, isolated abortifacient proteins α- and β-momorcharins, 537
Morphometric study on endometrial blood vessels, effect of norethisterone or levonorgestrel, 603
Multi-compartment vaginal ring system, independently adjustable release of contraceptive steroids, 589
Multinational multicentred clinical trials, 50

National reagent schemes, WHO Programme in Human Reproduction, 76
Natural regulation of fertility, "natural family planning", 23
Neoplasia and oral contraceptive use, 28
Nickel concentration,
during normal menstrual cycle, 395
effect of ethinylestradiol + norethisterone acetate, 395
Nonoxynol-9, concentration abolishing sperm motility, 207
Norethisterone,
morphometric study on endometrial blood vessels, 603
pharmacokinetic and pharmacodynamic study, 269
Norethisterone enanthate,
pharmacokinetic and pharmacodynamic studies, 26
return of fertility following discontinuation, 573
safety and efficacy studies, 26
Norethisterone level, use of "visiting pill" containing norethisterone, 269
Norplant® subdermal implant,
effect on androgen levels, 157
effect on thyroid function, 583
Norplant®-2 subdermal implant,
effect on androgen levels, 157
effect on thyroid function, 583
effects in breast-fed male infants, 403
Nurse-midwives vs. physicians, providers of IUD services, 44
Objectives, WHO Special Programme of Research, Development and Research Training in Human Reproduction, 3
Omission of ethinyl estradiol + levonorgestrel pill, effect on hypothalamo-pituitary-ovarian axis, 513
Omission of triphasic ethinyl estradiol + levonorgestrel pill, effect on hypothalamo-pituitary-ovarian axis, 513
Oral contraceptive,
assessment of medical risks and benefits, 7
effect on lactation, 7
ethinyl estradiol + ethynodiol diacetate, 121
ethinyl estradiol + levonorgestrel, 341, 513
ethinyl estradiol + norethindrone acetate, 121
ethinylestradiol + norethisterone acetate, 395
ethinyl estradiol + dl-norgestrel, 121
ethinyloestradiol + desogestrel, 135
interactions between use and diseases common in developing countries, 7
levonorgestrel, 403, 603
mestranol + norethisterone, 283
multicentre studies, 50
multicentred, multinational studies, especially developing countries, 7
norethisterone, 269, 603
risk factors in cardiovascular disease, 28
risk factors in neoplasia, 28
triphasic ethinyl estradiol + levonorgestrel, 135, 435, 513

Oral contraceptive use,
effect on vertebral bone mass in pre- and post-menopausal women, 333
study of determinants, 145
Oral contraceptive use by mothers, long-term follow-up of breast-fed children, 443
Ortho Creme®,
longevity of spermicidal potency in cervical cap, 363
longevity of spermicidal potency in contraceptive diaphragm, 381
Ovarian steroidogenesis, effect of RU486, 199
Ovary, effect of benzene extract of Hibiscus rosa-sinensis flower (mouse), 523
Ovulation detection methods, 23
Ovum transport and fertility regulation, 8
Pain at IUD insertion,
effect on subsequent performance, 497
patient risk factors, 483
Patents, WHO Programme in Human Reproduction, 80
Pelvic inflammatory disease, relation to IUD use, 31
Perforation of sigmoid colon by Cu-7 IUCD, 413
PG (prostaglandin)
$PGF_{2\alpha}$ + gossypol, effect on testis function and histology (rat), 177
Pharmacodynamic effects, levonorgestrel, 403
Pharmacokinetic parameters for ethinyl estradiol, administered in combination with levonorgestrel as table and as solution, 341
Pharmacokinetic parameters for levonorgestrel, administered in combination with ethinyl estradiol as tablet and as solution, 341
Pharmacokinetics, RU486, 469
Pharmacokinetics and pharmacodynamic effects, norethisterone, 269
Phenobarbital sodium, effect on postcoital contraceptive efficacy of ethinyl estradiol (rat), 191
16-Phenoxy-tetranor PGE_2 methyl sulfonylamide, use for preoperative cervical dilatation, 237
Phospholipids level,
effect of ethinyloestradiol + desogestrel, 135
effect of triphasic ethinyloestradiol + levonorgestrel, 135
Physicians vs. nurse-midwives, providers of IUD services, 44
Plants for fertility regulation, identification of orally active non-steroidal compounds of plant origin, 16
Postcoital contraceptive dose, ethinyl estradiol (rat), 191
Postcoital contraceptive efficacy of ethinyl estradiol, effect of diazepam or phenobarbital sodium (rat), 191
Postcoital IUD insertion, effectiveness as continuing contraceptive method, 549

Post-ovulatory methods of fertility regulation,
development of agents interfering with function of progesterone, 8
safety and efficacy, 30
use of prostaglandins, 8
Post-partum contraception, multicentre studies, 50
Post-partum sterilization by nurse-midwives, 42
Pre- and post-menopausal women, effect of oral contraceptive use on vertebral bone mass, 333
Pregnancy,
effect of aristolic acid (mouse), 625
effect of benzene extract of Hibiscus rosa-sinensis flower (mouse), 523
effect of IUD insertion-related problems, 497
use of benzalkonium chloride spermicidal suppository, 353
Pregnancy outcome, after use of levonorgestrel-releasing or TCu 380 Ag IUD, 261
Pregnancy rates, after use of levonorgestrel-releasing or TCu 380 Ag IUD, 261
Prentif cervical cap, longevity of Gynecol II® and Ortho Creme®, 363
Progesterone level,
effect of ethinyl estradiol + levonorgestrel, 513
effect of norethisterone, 269
effect of triphasic ethinyl estradiol + levonorgestrel, 513
Progesterone production by granulosa cells, effect of RU486, 199
Progestins with varying androgenic potency, effect on lipoproteins, 121
Programme for the Provision of Matched Assay Reagents, 72
d-Propranolol, concentration abolishing sperm motility, 207
Prostaglandin,
9-deoxo-16,16-dimethyl-9-methylene PGE_2, 237
16,16-dimethyl-trans-Δ_2-PGE_1, 459
16,16-dimethyl-trans-Δ_2-PGE_1 methyl ester, 237
15-methyl-$PGF_{2\alpha}$ methyl ester, 237
$PGF_{2\alpha}$ (rat), 177
16-phenoxy-tetranor PGE_2 methyl sulfonylamide, 237
use as post-ovulatory methods of fertility regulation, 8
Protein content and uterine weight, effect of aristolic acid (mouse), 625
Protein level, effect of mestranol + norethisterone, 283
Provision of equipment and supplies, WHO Programme in Human Reproduction, 77
Psychological behavior, children breast-fed by mothers using oral contraceptives, 443
Psychosocial and service research,
contraceptive use and behavior, 41
contributions having impact on policy, 41
(R,S)-3-chlorolactaldehyde, effect on metabolic activity of ejaculated spermatozoa (ram), 311
R5020, effect on progesterone production by granulosa cells, 199

Radioimmunoassay, RU486, 469, 613
Rate ratios, determinants of oral contraceptive use, 145
Recovery of fertility, after use of levonorgestrel-releasing or TCu 380 Ag IUD, 261
Relations with industry, WHO Programme in Human Reproduction, 78
Removal,
  effect of IUD insertion-related problems, 497
  use of IUDs, 559
Reproductive factors, effect on oral contraceptive use, 145
Research and devlopment, WHO Special Programme of Research, Development and Research Training in Human Reproduction, 4
Research and Training Centres, WHO network of clinical research centres in human reproduction, 50
Research training and training courses, WHO Programme in Human Reproduction, 68
Research Training Grants, WHO Programme in Human Reproduction, 68
Resources for research, WHO Special Programme of Research, Development and Research Training in Human Reproduction, 49
Return of fertility, following discontinuation of norethisterone oenanthate, 573
Risk factors associated with severe pain at IUD insertion, 483
Risk factors associated with technical failures in female sterilization using tubal ring procedure, 505
RU486 (17β-hydroxy-11β-(4-dimethylamino-phenyl)-17α-(1-propynyl)-estra-4,9-diene-3-one),
  effect on 3β-hydroxysteroid dehydrogenase activity, 199
  effect on progesterone production by granulosa cells, 199
  pharmacokinetic studies, 469
  quantitation by radioimmunoassay or high-performance-liquid chromatography after column chromatography, 613
  radioimmunoassay, 469
  use in early pregnancy termination, 459
RU486 + 16,16-dimethyl-trans-Δ_2-PGE_1, use in early pregnancy termination, 459
RU486 levels,
  after oral intake of various amounts of RU486, 613
  following oral administration to non-pregnant and early pregnant women, 469
(S)-α-chlorohydrin, effect on metabolic activity of ejaculated spermatozoa (ram), 311
Safety and efficacy, current methods of fertility regulation, 24
Schistosomiasis japonica, effect of mestranol + norethisterone on liver function tests of infected women, 283
Serious illness frequency, children breast-fed by mothers using oral contraceptives, 443
Service and psychosocial research,
  contraceptive use and behavior, 41
  contributions having impact on policy, 41

Sexual potentia, effect of danazol + testosterone enanthate (monkey), 417
SHBG (sex hormone binding globulin)
SHBG level,
effect of levonorgestrel, 157
effect of norethisterone, 269
Side effects,
depot-medroxyprogesterone acetate, 223
use of benzalkonium chloride spermicidal suppository, 353
use of prostaglandin analogues or laminaria tent for preoperative cervical dilatation, 237
use of RU486, 459
use of RU486 + 16,16-dimethyl-trans-Δ_2-PGE_1, 459
Sigmoid colon perforation by Cu-7 IUCD, 413
Socio-demographic characteristics, effect on oral contraceptive use, 145
Special issues, WHO Special Programme of Research, Development and Research Training in Human Reproduction, 77
Sperm motility,
effect of Allitridum, 295
effect of Allitridum (rat, hamster), 295
effect of chlorhexidine, 207
effect of gossypol (rat), 177
effect of gossypol + aspirin (rat), 177
effect of gossypol + $PGF_{2\alpha}$ (rat), 177
effect of gossypol acetic acid, 323
effect of gossypol acetic acid (monkey), 323
effect of nonoxynol-9, 207
effect of d-propranolol, 207
effect of spermicide used in cervical cap, 363
effect of spermicide used in diaphragm, 381
Sperm velocity,
effect of spermicide used in cervical cap, 363
effect of spermicide used in diaphragm, 381
Spermicidal effect, Allitridum, 295
Spermicidal potency,
longevity in spermicide-filled cervical cap, 363
longevity in spermicide-filled contraceptive diaphragm, 381
Spermicidal suppository containing benzalkonium chloride, use effectiveness, 353
Spermicide,
Gynecol II®, 363, 381
Ortho Creme®, 363, 381
Standardization and quality control, 72
Steel Ring, effect on menstrual blood loss, haemoglobin and ferritin concentration, 559
Sterilization, characteristics of women predisposing to failure using tubal ring procedure, 505
Subdermal implant contraceptive,
levonorgestrel, 157, 403, 583
multicentre studies, 50
safety and efficacy of Norplant®, 26

Summary, WHO Special Programme of Research, Development and Research Training in Human Reproduction over the past fifteen years, 92
Surgical sterilization techniques, assessment of safety and short-term sequelae, 33
TCu 220c, effect on menstrual blood loss, haemoglobin and ferritin concentraton, 559
TCu 380 Ag, recovery of fertility after use, 261
Termination,
  IUD users, 549
  postcoital IUD insertion, 549
Termination probability,
  IUD users, 549
  postcoital IUD users, 549
Termination rate, use of benzalkonium chloride spermicidal suppository, 353
Terminology, used in describing vaginal bleeding patterns, 253
Testicular biochemistry, effect of danazol + testosterone enanthate (monkey), 417
Testicular cell membranes, effect of gossypol (mouse), 639
Testicular histology, effect of danazol + testosterone enanthate (monkey), 417
Testicular histometry, effect of danazol + testosterone enanthate (monkey), 417
Testis function and histology,
  effect of gossypol (rat), 177
  effect of gossypol + aspirin (rat), 177
  effect of gossypol + $PGF_{2\alpha}$ (rat), 177
Testis functions, effect of danazol + testosterone enanthate (monkey), 417
Testosterone level,
  effect of levonorgestrel, 157
  in breast-fed male infants when levonorgestrel administered to lactating mothers, 403
Thyroid hormone parameters, effect of levonorgestrel, 583
Training courses and research training, WHO Programme in Human Reproduction, 68
Treatment of infertility,
  clomiphene citrate therapy in subfertile males, 40
  doxycycline and non-specific prostato-vesiculitis, 40
  mesterolone in subfertile males, 40
Triglycerides level,
  effect of ethinyloestradiol + desogestrel, 135
  effect of norethisterone, 269
  effect of triphasic ethinyl estradiol + levonorgestrel, 135, 435
  effects of oral contraceptives containing progestins with varying androgenic potency, 121
Triphasic vs. combination oral contraceptive, effect of deliberate pill omission on hypothalamo-pituitary-ovarian axis, 513
Tubal ring procedure for female sterilization, risk factors associated with technical failures, 505

Unit of analysis, used in describing vaginal bleeding patterns, 253
Use effectiveness, spermicidal suppository containing benzalkonium chloride, 353
User preference study of contraceptive methods, 44
Uterus,
  effect of aristolic acid (mouse), 625
  effect of benzene extract of Hibiscus rosa-sinensis flower (mouse), 523
Vaginal bleeding patterns induced by fertility regulating methods, analysis methods, 253
Vaginal contraceptive, benzalkonium chloride suppository, 353
Vaginal delivery systems for fertility regulation, 5
Vaginal irritation test, use of Allitridum (rabbit), 295
Vaginal ring contraceptive, multicentre studies, 50
Vaginal ring contraceptive system, releasing ethinylestradiol + 3-keto-desogestrel, 589
Vasectomy, possible sequelae, 32
Vasectomy by medical students, 42
Vasovasostomy, return of fertility, 32
VCu 200, effect on menstrual blood loss, haemoglobin and ferritin concentration, 559
Vertebral bone mass in pre- and post-menopausal women, effect of oral contraceptive use, 333
Visceral yolk sac morphology, effects of momorcharins (mouse), 537
Visiting Scientist Grants, WHO Programme in Human Reproduction, 68
Weight and height measurements, children breast-fed by mothers using oral contraceptives, 443
Weight change, use of depot-medroxyprogesterone acetate, 223
WHO (World Health Organization)
WHO network of clinical research centres of the Programme in Human Reproduction,
  centres collaborating with the Plant Task Force, 50
  centres coordinating specific projects, 50
  centres with specialized responsibilities, 50
  Collaborating Centres for Research, 50
  non-designated centres, 50
  Research and Training Centres, 50
Within-woman statistics, used in describing vaginal bleeding patterns, 253
World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction,
  first fifteen years, a review, 3
  future prospects, 90
  impact of the Programme, 84
  mandate, 3
  objectives, 3
  research and development, 4
  resources for research, 49
  special issues, 77
  summary of achievements over the past fifteen years, 92

Zygote transport, effect of aristolic acid (mouse), 625